Pazopanib versus paclitaxel in relapsed urothelial tumors: A randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive transitional cell carcinoma of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback